You are here

Shire

Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale

Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale

Endpoints

Flag link:

Takeda continues post-Shire selloff, inching closer to $10B goal

Takeda continues post-Shire selloff, inching closer to $10B goal

Endpoints

Flag link:

Once a gem, now just a rock, Takeda punts PhIII IBD drug as rivals muscle ahead

Once a gem, now just a rock, Takeda punts PhIII IBD drug as rivals muscle ahead

Endpoints

Flag link:

Takeda posts surprise profit a year after Shire mega-merger

Takeda posts surprise profit a year after Shire mega-merger

Pharmaforum

Flag link:

Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray

Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray

Endpoints

Oyster Point Pharma

dry eye disease

Flag link:

Former Shire execs set up shop to take a shot at 'under the radar' cancer target

Former Shire execs set up shop to take a shot at 'under the radar' cancer target

Endpoints

Flag link:

Takeda Pharmaceutical Raises Its Profit Outlook

Takeda Pharmaceutical Raises Its Profit Outlook

Motley Fool

Flag link:

Takeda puts Shire biologics plant with 200 employees on the block

Takeda puts Shire biologics plant with 200 employees on the block

Fierce Pharma

drug manufacturing

Flag link:

Takeda pares down products and jobs, revives Genzyme building plans

Takeda pares down products and jobs, revives Genzyme building plans

Bizjournals

Flag link:

Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200m

Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200m

Pharmaforum

Flag link:

Takeda breaks into top 20 largest pharmas with Shire merger

Takeda breaks into top 20 largest pharmas with Shire merger

Pharmaforum

Flag link:

Takeda eyes emerging markets asset sale to trim its debt; report

Takeda eyes emerging markets asset sale to trim its debt; report

Pharmaforum

emerging markets

Flag link:

Takeda staffers accuse drugmaker of favoring Shire employees during merger: report

Takeda staffers accuse drugmaker of favoring Shire employees during merger: report

Fierce Pharma

Flag link:

As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ in a restructured global organization

As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ in a restructured global organization

Endpoints

Flag link:

Takeda Eyes Additional Divestitures to Pare Down Shire Deal Debt

Takeda Eyes Additional Divestitures to Pare Down Shire Deal Debt

BioSpace

Flag link:

In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes

In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes

Endpoints

Flag link:

Servier, armed with Shire cancer drugs, builds out vision for U.S. future

Servier, armed with Shire cancer drugs, builds out vision for U.S. future

Fierce Pharma

Flag link:

Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal

Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal

Fierce Pharma

dry eye disease

Flag link:

Novartis Considers Offer for Takeda Eye-Disease Assets

Novartis Considers Offer for Takeda Eye-Disease Assets

Bloomberg

Flag link:

Pharma AbbVie, Shire investors agree to settle lawsuit over scuttled tax-inversion deal

Pharma AbbVie, Shire investors agree to settle lawsuit over scuttled tax-inversion deal

Fierce Pharma

Flag link:

Pages